EUVIMEDEUVIMED entdecken
Crossref

HHS announces new funding opportunities for psychedelics, with focus on ibogaine

Alison Knopf

Alcoholism & Drug Abuse Weekly · 23.11.2026 · 38 (45) · 4-6

DOI: 10.1002/adaw.35123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alcoholism & Drug Abuse Weekly, online erschienen am 20.11.2026. Verfasst von Alison Knopf.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Last week, the Department of Health and Human Services (HHS) announced two new investments to promote the development of psychedelics to treat mental illness. First, the National Institute of Mental Health (NIMH) published a $20 million notice of funding opportunity to support the development of a research network to study rapid‐acting psychotropic interventional drugs such as ketamine, esketamine, psilocybin and other emerging treatments for serious mental illnesses. Second, investments up to $4.9 million through the Advanced Research Projects Agency for Health (ARPA‐H) were announced to advance the development of ibogaine as a potential treatment for post‐traumatic stress disorder (PTSD) and other serious mental illnesses.

Zitieren

APA

Knopf, A. (2026). HHS announces new funding opportunities for psychedelics, with focus on ibogaine. Alcoholism & Drug Abuse Weekly, 38(45), 4-6. https://doi.org/10.1002/adaw.35123

Vancouver

Knopf A. HHS announces new funding opportunities for psychedelics, with focus on ibogaine. Alcoholism & Drug Abuse Weekly. 2026;38(45):4-6. doi:10.1002/adaw.35123

BibTeX
@article{Knopf2026,
  author = {Knopf, Alison},
  title = {HHS announces new funding opportunities for psychedelics, with focus on ibogaine},
  journal = {Alcoholism & Drug Abuse Weekly},
  year = {2026},
  volume = {38},
  number = {45},
  pages = {4--6},
  doi = {10.1002/adaw.35123}
}
Kostenlos starten →